Tests for suspected DLBCL: biopsy, staging and preparation for treatment

Testing for diffuse large B-cell lymphoma should answer four connected questions: is this lymphoma, which lymphoma is it, where is it present, and what treatment can the patient safely receive? A large lymph node, a high blood marker or an abnormal PET scan cannot answer all four. An organized work-up begins with an adequate biopsy and proceeds to staging and treatment preparation. Ordering every available test without a plan can create delays and unnecessary expense. [S1,S2]

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Removing an accessible lymph node often gives the pathologist useful tissue architecture and enough material for additional tests. A carefully planned image-guided core biopsy can be preferable when the mass is deep or surgery carries greater risk. The sampling team and laboratory should agree which material needs fixation and whether fresh tissue is required for flow cytometry. A small sample from a poorly chosen site may leave important questions unresolved. [S2]
Blood counts assess anemia, platelets and white cells. Lactate dehydrogenase provides relevant disease information but can rise for reasons other than lymphoma. Kidney and liver tests, electrolytes and uric acid help assess dosing and the risk of tumor lysis. A large, rapidly growing tumor burden or impaired kidney function may lead to closer monitoring when treatment begins. [S1]
The outcome of testing should be a clinical summary: the exact lymphoma name, stage, relevant risk features, treatment fitness, proposed regimen and outstanding questions. If results disagree, ask whether expert review or another biopsy is needed. The patient should not have to decide which report to believe. Assign responsibility for every pending result, especially if tissue review and treatment are being handled by different hospitals.

Quick answer

Full guide

Urgent symptoms change the order of work. Breathlessness, swelling of the face or neck, severe abdominal pain, major bleeding or new neurological problems require prompt clinical assessment. They should not wait for an ordinary international appointment. Tell the team about steroids, anticancer treatment, transfusions and recent infections, with dates. These can affect how tissue, laboratory results and scans are interpreted.

Plan the biopsy before the tissue is collected

Removing an accessible lymph node often gives the pathologist useful tissue architecture and enough material for additional tests. A carefully planned image-guided core biopsy can be preferable when the mass is deep or surgery carries greater risk. The sampling team and laboratory should agree which material needs fixation and whether fresh tissue is required for flow cytometry. A small sample from a poorly chosen site may leave important questions unresolved. [S2]

A fine-needle aspirate may show suspicious lymphoid cells without allowing reliable classification. If the report remains uncertain, ask whether the problem is insufficient tissue, damaged cells or a missing test. The next step should be chosen to solve that problem. Repeating the same inadequate procedure is not always the best approach. Before taking steroids on your own to shrink a lump, speak to the team because treatment can alter the tissue needed for diagnosis.

Understand the layers of the pathology work-up

Microscopic appearance is combined with immunohistochemistry to establish lineage and exclude competing diagnoses. Markers such as CD20, CD3, CD10, BCL6, MUM1, MYC, BCL2 and Ki-67 have different purposes. A list of positive stains is not a list of treatments. The pattern, cells involved and overall morphology matter. A hematopathologist may recommend additional testing for a specific differential diagnosis. [S3]

Flow cytometry can identify an abnormal cell population. FISH examines selected genetic rearrangements, while other molecular methods answer different questions. Tests for Epstein-Barr virus or a broader molecular panel may be appropriate in particular circumstances. A broad sequencing panel does not compensate for an uncertain tissue diagnosis. Ask what the proposed extra test could change: the disease name, the risk discussion, the regimen or eligibility for a study.

Separate protein expression from gene rearrangement

Immunohistochemistry reports expression of proteins, whereas FISH can identify rearrangements of genes such as MYC, BCL2 and BCL6. Double expression of MYC and BCL2 is not the same as a rearrangement-defined double-hit lymphoma. A high Ki-67 also does not substitute for FISH. Classification systems contain detailed distinctions, so keep the complete pathology wording rather than reducing the result to an informal label.

If an important result is still pending and the disease needs prompt treatment, the team may weigh starting therapy after adequate tissue has been obtained. Ask who will track the result and which findings would prompt reconsideration of the plan. Some testing can run in parallel; other findings are needed before a safe decision. Neither an indefinite wait for every optional test nor treatment based on an incomplete sample should be accepted without explanation. [S2,S3]

Use PET/CT to map disease and establish a baseline

FDG PET/CT commonly helps stage DLBCL and provides a comparison for response assessment. Uptake can occur in lymph nodes and other organs, but inflammation, infection and recent procedures can also produce abnormalities. A PET result is therefore not a replacement for biopsy. Sampling a second site may be worthwhile if it could identify a different lymphoma component, change staging or alter treatment. [S1]

Follow the imaging department's preparation instructions and report diabetes, recent infection, steroid use and growth-factor injections. Keep the full DICOM images as well as the written report. A few selected screenshots cannot provide the complete baseline for later interpretation. If PET/CT cannot be performed, ask which alternative imaging will be used and what limitations remain. Different test choices can be reasonable when they address the same clinical decision.

Ask whether bone marrow examination will change management

Bone marrow biopsy is not automatically necessary for every person with DLBCL. PET findings, unexplained low blood counts and concern for a separate indolent component can influence the decision. Some patients need marrow sampling to answer a question that imaging cannot resolve. Others may gain little additional information. Ask the doctor to identify the specific purpose rather than judging the quality of care by the number of procedures ordered. [S3]

A marrow aspirate and a core biopsy examine different aspects of the marrow. Tell the operator about anticoagulants, bleeding problems and previous difficulties with procedures. Follow the aftercare instructions for pressure, dressing and activity. The time to a full report depends on which additional laboratory studies are needed; the day of sampling is not necessarily the day a final integrated diagnosis can be issued.

Obtain laboratory results that support the first cycle

Blood counts assess anemia, platelets and white cells. Lactate dehydrogenase provides relevant disease information but can rise for reasons other than lymphoma. Kidney and liver tests, electrolytes and uric acid help assess dosing and the risk of tumor lysis. A large, rapidly growing tumor burden or impaired kidney function may lead to closer monitoring when treatment begins. [S1]

Do not independently start uric-acid medicines or force large volumes of fluid. People with heart or kidney disease may need a carefully measured plan. For an unfamiliar laboratory test, ask whether it informs drug dosing, admission, infection prevention or later monitoring. Keep the pretreatment values. When a blood count falls or liver enzymes rise during therapy, the original results help the doctor distinguish pre-existing abnormalities from new toxicity. [S20]

Check the heart and screen for infections before symptoms occur

A plan containing doxorubicin requires attention to cardiac history and appropriate baseline assessment, often including an ECG and echocardiogram. Previous heart failure, coronary disease, arrhythmia and earlier anthracycline exposure should be documented. Being able to walk without difficulty does not alone establish that every planned dose is safe. A cardiology opinion may help define the options when the initial assessment raises concerns. [S3]

Hepatitis B screening is relevant to rituximab-containing treatment and may lead to antiviral prevention and monitoring. Other infection tests are selected according to local protocols and the clinical setting. A patient who was told that hepatitis had resolved still needs the appropriate laboratory assessment. Active infection should be addressed promptly. During treatment, fever of 38°C or above or shaking chills warrants urgent contact with the team, particularly when neutrophils may be low. [S8]

Reserve central nervous system tests for a defined question

Persistent new headache, visual disturbance, weakness, seizures or changes in thinking can require neurological assessment and targeted imaging. Certain high-risk disease features may also lead to discussion of cerebrospinal fluid examination. Cytology and flow cytometry of the fluid provide different information. A routine PET report that does not mention brain disease does not rule out a neurological problem. [S3]

Not everyone without symptoms needs a lumbar puncture. Testing and central nervous system prophylaxis are related but separate decisions, and preventive treatment may affect kidney function, toxicity and the systemic treatment schedule. Ask why the procedure is proposed in your case. Before a lumbar puncture, the team needs to review platelet count, coagulation and anticoagulant medicines. Copying another patient's investigation list is not a substitute for a personal risk assessment.

Assemble records that another hospital can actually use

A useful review package includes the sampling site, original pathology report, complete immunohistochemistry and FISH pages, details of available slides or blocks, DICOM imaging and dated blood results with units. Translation should sit alongside the original documents. Do not replace uncertain wording with a definitive diagnosis or remove the laboratory's explanatory notes. An overseas pathologist needs to know what was tested and what remains untested.

Before shipping material, confirm the receiving laboratory's requirements and whether digital pathology is accepted. The originating hospital and receiving laboratory should agree the handling arrangements. For a China consultation, identify the purpose as pathology review, completion of staging or pretreatment assessment. Ask which existing tests can be accepted. Repeating everything may increase the bill without improving the decision. A written medical summary also supports subsequent follow-up. [S2,S12]

Plan time and cost by investigation, not by a package slogan

Biopsy, initial stains, external FISH testing and specialist review have different turnaround times. Request expected dates separately and mark which results are prerequisites to treatment. If there is organ compression or another urgent problem, the clinicians should identify the shortest safe pathway. An ordinary appointment queue does not establish how long the lymphoma can safely wait.

A quotation in Chinese yuan should separate consultation, biopsy and anesthesia, pathology stains, FISH, imaging, infection screening, cardiac tests and any admission. Ask whether international services and specimen shipping are included. This article does not have a verified patient-specific hospital quotation and cannot supply a dependable total. Accommodation, caregiver time and interruption of work also belong in the family budget because they affect continuity of treatment. [S10]

Finish with an integrated conclusion

The outcome of testing should be a clinical summary: the exact lymphoma name, stage, relevant risk features, treatment fitness, proposed regimen and outstanding questions. If results disagree, ask whether expert review or another biopsy is needed. The patient should not have to decide which report to believe. Assign responsibility for every pending result, especially if tissue review and treatment are being handled by different hospitals.

Fertility, nutrition and practical support should be discussed before the first cycle when possible. A future clinical-trial assessment may require complete baseline information, but research-only sampling needs informed consent and a clear explanation of its purpose. Keep a copy of the integrated assessment with the original reports. That record helps the next team understand why the treatment was chosen and avoids unnecessary reconstruction of the diagnostic process. [S9,S16]